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Reactive oxygen species (ROS) is required for cardiomyocyte differentiation 
from embryonic stem cells. However, whether ROS plays a role in erythropoiesis 
remains unclear. Using a well-established in vitro erythropoiesis model, we found 
that ROS was produced during erythropoietin (EPO)-induced differentiation of TF-1 
human erythroleukemia cells, with a peak at Day 4. Antioxidant vitamin E abolished 
this ROS production but did not inhibit the expression of erythroid marker 
glycophorin A (GPA), implying a nonessential role of ROS in the EPO-induced 
erythropoiesis. In search for the possible role of ROS, we found that it was not the 
cause of mitochondrial depolarization, a non-apoptotic requirement during 
erythropoiesis. It was neither the cause of cell death. 
To survive under one of the highest level of oxidative stress conditions when 
transporting oxygen, erythrocytes acquire strong antioxidant defense systems during 
differentiation. We hypothesized that the observed ROS production contributed to 
the establishment of such resistance. It was found that differentiating cells gradually 
became resistant to H2O2 challenging and such resistance was not developed when 
cells had been treated with antioxidants during differentiation. In concert with this, 
various antioxidant enzymes and related proteins were upregulated during TF-1 
XV 
erythropoiesis, especially glutathione peroxidase (GPx), thioredoxin (Trx) and 
glucose transporter type 1 (Glutl), while co-treatment of cells with antioxidants 
partially abolished this effect. 
Based on these observations, we conclude that through the induction of 
various antioxidant enzymes and related proteins, ROS production during 
erythropoiesis confers strong antioxidant defense on erythrocytes to cope with one of 
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Chapter 1 Introduction 
l.l.Erythropoiesis 
Erythropoiesis is the process in which hematopoietic stem cells (HSCs) 
differentiate into erythrocytes. The development is triggered via the expression of the 
erythropoietin receptor (EPOR) and its activation by erythropoietin (EPO). The 
process involves eight recognizable morphological stages, namely burst-forming 
unit-erythroid (BFU-E), colony-forming unit-erythroid (CFU-E), proerythroblast 
(Pro EB), basophilic erythroblast (Baso EB)，polychromatophilic erythroblast (Poly 
EB)， orthochromatic erythroblast (Ortho EB), reticulocyte (RET), and 
erythrocyte/red blood cell (RBC) (Koury et al., 2002) (Figure 1.1). The human 
erythrocyte is the most abundant cell type in the body: approximately 25 trillion 
erythrocytes course through the human circulatory system. Their main function is the 
transport of oxygen and the mediation of CO2 production. The mature erythrocyte is 
also one of the most specialized cells in the body. During erythropoiesis, the cell 
loses its nucleus, ribosomes, and mitochondria and therefore all capacity of cell 
division, protein synthesis, and mitochondrial-based oxidative reactions (Cimen, 
2008). Defects in erythropoiesis can lead to different types of anemia or leukemia. 
Thus, the delicate regulatory mechanism underlying erythropoiesis is the focus of 
this study. 
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1.2. The TF-1 model 
TF-1 is a human erythroleukemia cell line that was established in 1989 
(Kitamura et al., 1989). The normal proliferation of these cells at CFU-E stage can be 
maintained by granulocyte-macrophage colony stimulating factor (GM-CSF) or 
interleukin-3 (IL-3). Upon EPO stimulation, the cells begin to differentiate along the 
erythroid lineage, going through Pro EB, Baso EB stages and stop at the Poly EB 
stage (Drexler et al., 2004). 
As a cancer cell line, the TF-1 cells are unable to go through the terminal 
erythroid differentiation, i.e. the enucleation process, partially due to the 
overexpression of a truncated form of EPOR in these cells (Chretien et al., 1996; 
Ward et al., 1992; Winkelmann et al., 1995). To date, reprogramming 
erythroleuekmia cells to terminal differentiation and terminal cell division is only 
possible on some murine erythro leukemia cell models but not human models 
(Ghysdael et al., 2000; Matushansky et al, 2000). Thus, the TF-1 model remains to 
be one of the best in vitro models in studying human erythropoiesis. 
In addition, our lab has previously investigated the roles of caspase-3 and 
heat shock protein 70 (Hsp-70) in erythropoiesis based on the TF-1 model (Lui and 
Kong, 2006, 2007). Thus, the TF-1 model was also chosen in this study as the 
experimental platform. 
3 
Chapter 1 Introduction 
1.3. The erythroid marker glycophorin A (GPA) 
In order to discriminate cells undergoing erythroid differentiation from 
undifferentiated cells, an erythroid-specific cell surface marker is required. A 
membrane sialoglycoprotein GPA (CD235a), one of the most commonly used 
erythroid markers, was selected in this study (Koury et al., 2002; Nakahata and 
Okumura, 1994). During erythropoiesis, the expression of GPA gradually increases 
from the Pro EB stage and finally becomes a major component in matured 
erythrocyte membrane (Nakahata and Okumura, 1994). GPA contains large numbers 
of sialic acid and M N blood group structures (Gahmberg et al , 1979). In 
proliferating undifferentiated TF-1 cells, around 15% express GPA. During EPO-
induced erythropoiesis, the percentage of cells expressing GPA gradually increases, 
reaching about 65% after 8 days of EPO treatment. It is noteworthy that even on Day 
8 of differentiation 35% of the cells were GPA negative, indicating that they were 
undifferentiated cells. In order to ensure the accuracy of observations, this cell 
population had to be separated from the differentiating population in future assays 
with the help of GPA labeling. 
1.4. Reactive oxygen species (ROS) 
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ROS are oxygen-centered molecules with unpaired electrons. Intracellular 
ROS generally include non-radicals such as hydrogen peroxide (H2O2), other 
peroxides (ROOH), singlet oxygen ('O2) and nitric oxide (NO), as well as radicals 
such as superoxide anion (CV—)，hydroxyl radical (0H'), peroxyl radical (R00') and 
peroxynitrite anion (0N00~). The conversion of major ROS are listed in Figure 1.2 
(Ghaffari, 2008). ROS are continuously formed in small amounts by normal 
metabolic processes and are known to play important roles in phagocytosis, 
inflammation, aging, tissue repair and intracellular signaling. However, i f 
uncontrolled, excessive ROS can exert detrimental effects to cellular organelles and 
molecules, including DNA strand breakage, damage to enzymes and other proteins 
and lipid peroxidation (Cimen, 2008). For example, during oxidative stress, there 
may be an increased level of oxidized protein cysteines, which may lead to 
inactivation of phosphatases and transcription factors (Day, 2009). In addition, it has 
been known that oxidized nucleotides can rapidly induce cell senescence (Rai et al.， 
2009). 
ROS are ideal intracellular signaling molecules because they are rapidly 
generated, highly diffusible and easily degraded. ROS have been known to promote 
differentiation in lens cells, neurons and cardiomyocytes (Sauer et al., 2001). ROS 
also have been reported to be a mediator of chemical-induced erythroid 
5 
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differentiation of K562 human leukemia cells (Chenais et al, 2000). In addition, 
exogenous ROS have been suggested to stimulate the differentiation of K562 cells in 
vitro (Nagy et al., 1995). However, it remains unknown whether endogenous ROS 
play a role in EPO-induced erythropoiesis. 
1.5. Oxidative stress in human erythrocytes 
As a consequence of their physiological role, circulating RBCs are exposed to 
continuous oxidative stress due to the high O2 tension in arterial blood and their 
abundant heme Fe content. The source of ROS in erythrocytes is the oxygen carrier 
hemoglobin (Hb). Occasional reduction of O2 to 02*' is accompanied by oxidation of 
Hb to metHb, a rustbrown-colored protein that does not bind O2 (Figure 1.3). In 
addition, ROS initiate lipid peroxidation reactions that lead to loss of membrane 
integrity and cell death (Dumaswala et al, 1999). Therefore, antioxidant defense 
systems play a crucial role in maintaining red cell function. In specific, it has been 
demonstrated that the glutathione peroxidase (GPx) system provides the primary 
antioxidant defense in RBCs stored in blood bank (Dumaswala et al., 1999). 
1.6. Antioxidant defense systems 
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Cellular antioxidant defense systems control the level of ROS and thus 
protect the cells from oxidative damage. The antioxidant system consists of 
enzymatic and non-enzymatic pathways. 
Enzymatic antioxidants include superoxide dismutase (SOD) and peroxide 
scavenging enzymes. SOD is a family of antioxidant enzymes comprising 
Cu/ZnSOD, MnSOD and extracellular SOD. Their role is to convert O2— to H2O2 
and O2. Cu/ZnSOD localizes to cytosol whereas MnSOD localizes to mitochondria. 
On the other hand, peroxide scavenging systems comprise at least three pathways. 
They are catalase, the GPx system and the peroxiredoxin (Prx) system (Day, 2009) 
(Figure 1.4). 
Catalase catalyzes the detoxification of H2O2 or other peroxides (ROOH) into 
water or corresponding alcohol (ROH). The GPx system comprising GPx, 
glutathione (GSH) and glutathione reductase (GSR) is a key defense against 
peroxides. During a catalytic cycle, GPx reduces the toxic peroxides into water or 
ROH. The oxidized GPx is reduced by two GSH which are in turn oxidized to 
glutathione disulfide (GSSG). The GSSG is converted back to two GSH by GSR that 
uses reducing equivalents derived from NADPH. The Prx system includes Prx, 
thioredoxin (Trx) and thioredoxin reductase (TrxR). The catalytic cycle is similar to 
that of the GPx system, which also utilizes NADPH as the reducing power. In turn, 
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NADPH is generated from the pentose phosphate pathway (PPP) (Veal et al., 2007) 
(Figure 1.3). In addition, the GPx and Prx systems also maintain cellular protein 
cysteines in a reduced state. 
Non-enzymatic antioxidants can be separated into two categories: lipophilic 
(vitamin E, vitamin A, coenzyme QIO, melatonin, etc.) and water soluble (vitamin C, 
uric acid, ceruloplasmin, transferrin, haptoglobulin, etc.) (Cimen, 2008). Vitamin C 
can donate a hydrogen atom to a free radical molecule thereby neutralizing it. 
Vitamin E is the most effective antioxidant for terminating the chain reactions of 
lipid peroxidation in cell membranes. Coenzyme QIO or vitamin C regenerates 
vitamin E, and vitamin C is regenerated by GSH or lipoic acid, which are in turn 
regenerated by NADPH or NADH. Generally speaking, non-enzymatic antioxidants 
scavenge ROS radicals and singlet oxygen instead of neutralizing peroxides. 
NADPH not only provides reducing equivalents for peroxide scavenging 
systems. In fact, human catalase contains four tightly bound molecules of NADPH 
which are necessary for enzymatic activity (Kirkman and Gaetani, 1984). 
Furthermore, NADH and NADPH are used to regenerate non-enzymatic antioxidants 
such as vitamin C. Thus, these energy-containing molecules become the cell's 
ultimate reducing power against oxidative stress. 
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Antioxidant defense systems are particularly important for RBCs. 
Compromised protection from ROS, as seen in genetic deficiencies involving 
antioxidant enzymes or their transcription activators such as Prxl, Prx2, MnSOD, 
Nrf2 or Fox03, results in shortened erythrocyte life span and hemolysis, which in 
some cases lead to anemias (Friedman et al., 2001; Lee et al.，2004; Low et al.，2008; 
Marinkovic et al., 2007; Neumann et al., 2003). 
1.7. Glucose provides the majority of reducing equivalents in human 
erythrocytes 
Glucose is the only fuel utilized by mature erythrocytes. Approximately 80-
90% of intracellular glucose is converted to lactate via the glycolytic pathway, while 
the remaining 10% undergoes oxidation via the PPP pathway (Cimen, 2008). Much 
of the glucose metabolism is geared to the production of NADPH and NADH 
through the PPP and glycolytic pathway, respectively. In erythrocytes, NADPH 
provides reducing equivalents in the reduction of H2O2 and other peroxides, while 
NADH assists metHb reductase to reduce metHb to functional Hb (Figure 1.3). 
The loss of reducing equivalents can result in significantly reduced defense to 
oxidative stress. An apt example is glucose-6-phosphate dehydrogenase (G6PD) 
deficiency, the most commonly inherited enzyme abnormality in humans. G6PD is 
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responsible for the first enzymatic reaction of the PPP pathway. Patients with G6PD 
deficiency are thus unable to convert glucose along the PPP pathway. In erythrocytes, 
the PPP is the only source ofNADPH production. As a result, NADPH production is 
diminished in the erythrocytes of G6PD patients. Because of the severely reduced 
ability to scavenge ROS in erythrocytes, these patients have increased sensitivity to 
ROS generating agents and have the possibility to develop acute hemolytic anemia 
under oxidative stress. 
1.8. Glucose transporter type 1 (Glutl) transports glucose and vitamin C into 
human erythrocytes 
The transport of glucose in or out of cells is mediated by two major families 
of glucose transporters, namely facilitative glucose transporters (Glut) and 
concentrative Na+/glucose transporters (SGLT). Glut proteins facilitate passive 
diffusion of glucose across tissue barriers by energy-independent stereo-specific 
mechanisms. The Glut family includes 12 SLC2A genes encoding 12 Glut proteins, 
numbered 1-12 (Pascual et al., 2004). Glutl protein belongs to the facilitative 
glucose transporter class 1, consisting of 492 amino acids which form 12 alpha-
helical trans-membrane domains. It is a basal glucose transporter with a low K,„ for 
glucose (1-2 mM) that is highly expressed in the brain and erythrocytes while 
10 
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ubiquitously expressed and transport glucose in many mammalian cell types 
(McGowan et al., 1995). 
Of all cells, human erythrocytes express the highest level of the Glutl glucose 
transporter, and Glutl is the sole glucose transporter in human erythrocytes 
(Devaskar and Mueckler, 1992). In addition, human erythrocyte Glutl mediates the 
uptake of L-dehydroascorbic acid (DHA), an oxidized form of ascorbic acid (vitamin 
C) (Montel-Hagen et al., 2008) (summarized in Figure 1.3). 
1.9. Hypothesis and objectives 
In this study, it was hypothesized that ROS was produced during TF-1 
erythropoiesis, which played positive roles in maintaining normal erythroid 
differentiation. 
The main objectives of this project were: 
1. To study ROS production in different subpopulations of TF-1 cells during 
EPO-induced erythropoiesis by flow cytometry. 
2. To investigate the possible roles of ROS production by antioxidant treatments 
of the TF-1 cells during EPO-induced erythropoiesis by flow cytometry and 
Western blot. 
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1.10. Long-term significance 
The findings of this study may help elucidate the mechanisms underlying 
erythropoiesis, and contribute to the development of treatments for blood diseases 
such as glucose-6-phosphate dehydrogenase (G6PD) deficiency, anemia or leukemia. 
12 
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HSC BFU-E CFU-E Pro EB Baso EB Poly EB Ortho EB RET RBC 
Figure 1.1. Stages of mammalian erythropoiesis. Adapted from (Koury et al” 
2002). 
Abbreviations: HSC, hematopoietic stem cell; BFU-E, burst-forming unit-erythroid; 
CFU-E, colony-forming unit-erythroid; Pro EB, proerythroblast; Baso EB, basophilic 
erythroblast; Poly EB, polychromatophilic erythroblast; Ortho EB, orthochromatic 
erythroblast; RET, reticulocyte; RBC, red blood cell 
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Figure 1.2. Conversion of major ROS. Adapted from (Ghaffari, 2008). 
Abbreviations: 'O2, superoxide anion; SOD, superoxide dismutase; H2O2, hydrogen 
peroxide; 'OH, hydroxyl radical; GSH, glutathione; GSSG, glutathione disulfide; 
GPX, glutathione peroxidase; MPD, myeloperoxidase; HOCI, hypochlorous acid; 
'O2, singlet oxygen 
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Figure 1.3. Major oxidative defense in human erythrocytes. 
Abbreviations: Glu，glucose; Glutl, glucose transporter type 1; GPx, glutathione 
peroxidase; H2O2, hydrogen peroxide; Hb, hemoglobin; Met-Hb, Met-hemoglobin; 
NAD+，nicotinamide adenine dinucleotide; NADH, reduced nicotinamide adenine 
dinucleotide; NADP+, nicotinamide adenine dinucleotide phosphate; NADPH, 
reduced nicotinamide adenine dinucleotide phosphate; 62'", superoxide anion; 
Ribose 5-P, ribose 5-phosphate; VitC, vitamin C 
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Figure 1.4. Peroxide scavenging systems. Adapted from (Day, 2009). 
Abbreviations: GPx, glutathione peroxidase; GSH, glutathione; GSH Reductase, 
glutathione reductase; GSSG, glutathione disulfide; H2O2, hydrogen peroxide; 
NADP+， nicotinamide adenine dinucleotide phosphate; NADPH, reduced 
nicotinamide adenine dinucleotide phosphate; Prx, peroxiredoxin; ROH, 
corresponding alcohols; ROOH, peroxides; Trx, thioredoxin; Trx Reductase, 
thioredoxin reductase 
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2.1. Cell culture 
2.1.1. Culture media 
M 
The RPMI medium 1640 (Invitrogen 23400-021) was supplemented with 2.5 g/L 
glucose and 2 g/L sodium bicarbonate (pH 7.2). The medium was filtered by passing 
through a Steritop-GP Filter (Millipore) and was stored at 4 °C for up to three 
months. 
M2(-) 
The M medium was supplemented with 1 mM sodium pyruvate, 10% FBS and 1% 
penicillin-streptomycin (all sterile) and was stored at 4 °C for up to one month. 
M3 
The M2(—) medium was supplemented with 3 ng/ml GM-CSF (Sigma G5035) and 
stored at 4 °C before use. 
M2 
The M2(-) medium was supplemented with 10 ng/ml EPO (Calbiochem 329871) 
immediately before use. 
Phenol red free RPMI (pRPMI) 
Phenol red free RPMI (Sigma R8755) was supplemented with 2.5 g/L glucose and 2 
g/L sodium bicarbonate (pH 7.3). The Sigma R8755 might not dissolve well under 
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normal pH, so the pH was first lowered to 4.0 for total dissolve of the powers, then 
raised back to 7.3 prior to the addition of sodium bicarbonate. The medium was 
filtered by passing through a Steritop-GP Filter (Millipore) and was stored at 4 °C for 
up to six months. 
2.1.2. Cell maintenance 
Growth factor dependent, EPO sensitive human erythroleukemic cells TF-1 (ATCC 
CRL-2003) were maintained in M3 medium at a density of IxlO"^ to 4x10^ cells/ml 
and were kept in 37 °C, 5% CO2 incubator with humidified atmosphere. Under 
optimal conditions, the doubling time of the cells was around 24 h. Renewal of 
medium was done every 2-3 days. In each passage, cells were pelleted by 
centrifugation at 1500 rpm for 3 min at RT (Eppendorf Centrifuge 581 OR). After 
long time culture, the significant elongation of doubling time indicated the 
senescence of the cells. A new line should be thawed for replacement. 
2.1.3. Cell cryopreservation 
To prepare the frozen stock of cells, 5x10^ cells were resuspended in 0.5 ml freezing 
medium containing 95% M3 medium (v/v) and 5% DMSO (v/v) and transferred to 
freezing vials (Nalgene). The vials were kept at RT for 15 min to allow equilibrium. 
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The vials were then wrapped with parafilm and transferred to Cryo 1 °C Freezing 
Container (Nalgene) and placed in -80 °C freezer overnight. The freezing container 
cooled at 1 °C per minute. In the next day, the vials were transfered to liquid nitrogen. 
It was recommended that the vials be stored in the gas phase above the nitrogen (— 
178 °C to -150 °C) to be absolutely safe. 
To thaw cells, 0.5 ml M3 medium was directly added into the freezing vial to thaw 
the freezing medium. The content of the vial was then mixed with 4 ml M3 medium 
and the cell pellet was collected by centrifugation. The cells were ready for use after 
passage for at least one week. 
2.1.4. Cell differentiation 
Prior to induction of differentiation, cells were starved in M2(-) medium at a density 
of 4x10^ cells/ml for 16 h. The time after starvation was considered as Day 0. The 
cells were then cultured in M2 medium for 8 days at a density of 4x10^ cells/ml. 
Renewal of medium was done every two days. The color of the cell pellet should 
change from white (Day 0) to red (begin from Day 4)，indicating cell differentiation 
along the erythroid lineage. 
2.1.5. Cell treatments 
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Unless otherwise specified, all chemicals used to treat the cells during differentiation 
were first dissolved in PBS or DMSO as stock, then diluted in M2 medium and 
applied to cell culture. The final concentration of PBS or DMSO did not exceed 0.2% 
(v/v). 
2.1.5.1. Antioxidant treatments 
Different antioxidants were applied to cell culture during the course of differentiation, 
including vitamin C (Sigma A5960), vitamin E (Sigma T3251), NAC (Sigma A7250), 
ebselen (Cayman 70530), EUK-134 (Cayman 10006329) and apocynin (Sigma 
A10809). The concentrations of antioxidants used in this study were adopted from 
recent literatures which investigated similar questions on cultured human cells 
(Buggisch et al., 2007; Duarte and Jones, 2007). Vitamin C (100 ^iM) and vitamin E 
(100 [iM) are neutralizers to ROS radicals such as 0 2 - , OH., ROO.，0N00-. NAC 
(5 mM) is a GSH precursor which acts in the GPx system to diminish peroxides, so is 
ebselen (10 |LIM), a GPx mimic. EUK-134 (50 ^IM) is a SOD and catalase mimic and 
is thus capable of removing both ROS radicals and peroxides. Apocynin (100 |aM) is 
a NADPH oxidase inhibitor. Renewal of antioxidants was done every two days 
together with the renewal of M2 medium. 
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2.1.5.2. H2O2 challenging 
H2O2 challenging was adopted to test the oxidative defense strength of differentiating 
erythroblasts. For each sample, 4x10^ cells were washed twice with ice-cold PBS 
and pelleted by centrifugation at 2500 rpm for 3 min at 4 °C (Eppendorf Centrifuge 
5417R). The cells were then resuspended in 1 ml M2 medium containing 2 mM H2O2 
and then cultured for 9 h. Subsequently, analysis of cell death by flow cytometry was 
performed as described in Section 2.2.7. Titration and time series were performed to 
define the concentration of H2O2 (250 pM, 500 ^iM, 1 mM, 2 mM) and incubation 
time (1 h, 3 h, 6 h, 9 h, 12 h，24 h) to achieve a wide dynamic range in detecting cell 
death. 
2.1.5.3. Antibiotic treatment 
Levofloxacin, a prevalently used fluoroquinolone antibiotic, was applied to cell 
culture during the course of differentiation to test its inhibitory effects on Glutl and 
glucose transport. Levofloxacin was added at clinical mean plasma concentration 
(7.06 |iM) (Tumidge, 1999). Renewal of the antibiotic was done every two days 
together with the renewal of M2 medium. 
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2.2. Flow cytometry 
2.2.1. Flow cytometers 
A FACSCanto (BD Biosciences) was used in most experiments except FACS cell 
sorting. The cell sorting experiments were performed with a FACSVantage SE (BD 
Biosciences). 
2.2.2. Analysis of erythroid differentiation 
Cell differentiation was evaluated by staining of erythroid lineage cell surface marker 
GPA with anti-human GPA mouse monoclonal antibody conjugated with either 
FITC (Pharmingen 559943), PE (Pharmingen 555570) or APC (BioLegend 306607). 
For each sample, 5x10^ cells were washed twice with ice-cold PBS and pelleted by 
centrifugation at 4300 rpm for 3 min at 4。C (Eppendorf Centrifuge 5417R). The 
cells were then resuspended in 0.5 ml PBS containing 100 |ag/ml mouse IgG and 5 
mg/ml BSA and incubated for 30 min on ice. Anti-GPA antibody was then added 
into the samples at a dilution of 1:500. The cells were further incubated for 30 min 
on ice in dark. Subsequently, the cells were washed with ice-cold PBS for three times 
and subjected to flow cytometry analysis. Signals for FITC, PE or APC were 
collected from the respective channels. 
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2.2.3. Analysis of cell lineage 
Cell lineage analysis was carried out using a permanent dye CFSE (Invitrogen 
CI 157). On Day 0 (after 16 h starvation), 5x10^ cells were washed twice with PBS 
and pelleted by centrifugation at 1500 rpm for 3 min at RT (Eppendorf Centrifuge 
581 OR). The cells were then resuspended in 1 ml PBS. The CFSE solution was 
prepared immediately before use and 1 ml solution was added into the cell 
suspension. The final concentration of CFSE was 5 |LIM. The samples were mixed 
well immediately by vortex and then incubated for 5 min at RT in dark. Subsequently, 
the cells were washed with 20 ml M2(-) medium for three times and then cultured in 
M2 medium to induce differentiation. The cells were collected every two days, 
washed and subjected to flow cytometry analysis. Signal for CFSE was collected 
from the FITC channel. 
2.2.4. Analysis of intracellular ROS 
Intracellular ROS levels were measured by using the fluorescent dyes CM-
H2DCFDA (Invitrogen C6827), DHE (Invitrogen D1168) and MitoSOX (Invitrogen 
M36008). CM-H2DCFDA detects hydrogen peroxide (H2O2), hydroxyl radicals 
(H0-), peroxyl radicals (ROO ) and peroxynitrite anions (0N00- ) . DHE detects 
superoxide anions (• 02- ) and MitoSOX specifically localizes to the mitochondria 
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and detects mitochondrial production of superoxide anions. For each sample, 5x10^ 
cells were washed twice with ice-cold PBS and pelleted by centrifligation at 4300 
rpm for 3 min at 4 °C (Eppendorf Centrifuge 5417R). The cells were then 
resuspended in 0.5 ml PBS containing 5% FBS (v/v) and either CM-H2DCFDA (10 
laM)，DHE (10 |liM) or MitoSOX (5 ^iM). The samples were incubated for 30 min at 
37 °C in dark. Subsequently, the cells were washed and subjected to flow cytometry 
analysis. Signals for CM-H2DCFDA (FITC)，DHE (PE) or MitoSOX (PE) were 
collected from the respective channels as indicated in the brackets. 
2.2.5. Analysis of mitochondrial transmembrane potential (ATm) 
A中m was quantified by using the fluorescent dye TMRM (Invitrogen T668). For 
each sample, 5x10^ cells were washed twice with ice-cold PBS and pelleted by 
centrifligation at 4300 rpm for 3 min at 4 � C (Eppendorf Centrifuge 5417R). The 
cells were then resuspended in 0.5 ml pRPMI medium containing 10% FBS (v/v) and 
TMRM (500 nM). The samples were incubated for 30 min at 37 °C in dark. 
Subsequently, the cells were washed and subjected to flow cytometry analysis. 
Signal for TMRM was collected from the PE channel. 
2.2.6. Analysis of mitochondrial mass 
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Mitochondrial mass of living cells were quantified using the fluorescent dye NAO 
(Invitrogen A1372). NAO binds to cardiolipin on the inner mitochondrial membrane 
and is thus mitochondrion-specific. The binding is not affected by A平m (Metivier et 
al., 1998). For each sample, 5x10^ cells were washed twice with ice-cold PBS and 
pelleted by centrifugation at 4300 rpm for 3 min at 4 °C (Eppendorf Centrifuge 
5417R). The cells were then resuspended in 0.5 ml pRPMI medium containing 10% 
FBS (v/v) and NAO (10 [xM). The samples were incubated for 10 min at 37 °C in 
dark. Subsequently, the cells were washed and subjected to flow cytometry analysis. 
Signal for NAO was collected from the FITC channel. 
2.2.7. Analysis of cell death 
Cell death was determined by using the fluorescent protein annexin V-GFP or 
double-staining the cells with annexin V-GFP and PI (Sigma P4170). For each 
sample, 5x10^ cells were washed twice with ice-cold PBS and pelleted by 
centrifugation at 4300 rpm for 3 min at 4 °C (Eppendorf Centrifuge 5417R). The 
cells were then resuspended in 0.5 ml annexin V binding buffer (0.01 M 
HEPES/NaOH, 140 mM NaCl, 25 mM CaCb, pH 7.4) with annexin V-GFP (32 
}ig/ml). The samples were incubated for 15 min at RT in dark. Optionally, PI was 
then added into the binding buffer at final concentration of 2 |j,g/ml and incubated for 
26 
Chapter 2 Materials and Methods 
4 min at RT in dark. Subsequently, the cells were directly subjected to flow 
cytometry analysis. Signals for annexin V-GFP and PI were collected from the FITC 
and PerCP channels, respectively. 
2.2.8. Analysis of caspase-3 activity 
Caspase-3 activity of living cells were quantified using the APO LOGIX 
Carboxyfluorescein Caspase Detection Kit, which employed the covalent bonding 
between active caspase-3 and a cell peameable fluorescent caspase-3 inhibitor FAM-
DEVD-FMK. For each sample, 3x10^ cells were washed twice with ice-cold PBS 
and pelleted by centrifugation at 4300 rpm for 3 min at 4 °C (Eppendorf Centrifuge 
5417R). The cells were then resuspended in 0.3 ml pRPMI medium containing 10% 
FBS (v/v) and 10 ul 3OX FAM-DEVD-FMK. The samples were incubated for 1 h at 
37 °C in dark. Subsequently, the cells were washed twice with wash buffer and then 
subjected to flow cytometry analysis. Signal for FAM-DEVD-FMK was collected 
from the FITC channel. 
2.2.9. FACS cell sorting 
Differentiating erythroblasts were separated from undifferentiated cells by FACS cell 
sorting. For each sample, 5x10^ cells were washed twice with ice-cold PBS and 
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pelleted by centrifugation at 3000 rpm for 3 min at 4 °C (Eppendorf Centrifuge 
581 OR). The cells were then resuspended in 5 ml PBS containing 100 |j,g/ml mouse 
IgG and 5 mg/ml BSA and incubated for 30 min on ice. Anti-GPA-PE antibody was 
then added into the samples at a dilution of 1:500. The cells were further incubated 
for 30 min on ice in dark. Subsequently, the cells were washed with ice-cold PBS for 
three times and subjected to FACS cell sorting on the PE channel according to the 
intensity of PE labeling. GPA+ cells were regarded as differentiating cells whereas 
GPA- cells were undifferentiated cells. The GPA levels of sorted samples were 
confirmed by another flow cytometer FACSCanto. 
2.2.10. Two-variant flow cytometric experiments 
In most experiments, cells were stained by two dyes to discern phenotypically 
complex cell populations. For each two-variant flow cytometric experiment, the 
procedure was the sum of two single-staining procedures as listed above, with the 
following orders: CFSE -> GPA / CM-H2DCFDA GPA / TMRM + GPA / 
Annexin V-GFP GPA / FAM-DEVD-FMK GPA / CFSE -> CM-H2DCFDA / 
CFSE TMRM / CM-H2DCFDA TMRM / TMRM Annexin V-GFP. 
2.2.11. Analysis of flow cytometry data 
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Data were analyzed using the Flow Jo software free trial version (downloaded from 
http://www.flQwjo.cQmA. In the analysis, positive-staining cell population was 
separated from negative-staining cell population by either rectangular or quadrant 
gates based on the staining pattern of negative and/or positive controls, as indicated 
in the data graph. 
2.2.12. Compensation 
In any double-staining experiments that involving both FITC/PE or FITC/PerCP 
channels, compensation was carried out to avoid emission spectra overlap. Single-
dye stained samples acted as positive control and non-stained sample acted as 
negative control. The compensation matrixes were generated by the FlowJo software 
and applied to double-staining samples, as listed below: 
2.2.12.1. Compensation matrix for Annexin V-PI double-staining 
<CompensationMatrix name="20080510 AnnexinV 1 50 PI 2 ugml (300 450) 
PerCP.mtx" prefix="Comp-" suffix=”” version="Version 5.7.2"〉 
<Channel name="FITC-A"> 
<ChannelValue name="FITC-A" value=" 1.00000" /> 
<ChannelValue name="PerCP-Cy5-5-A" value=”0.05176" /> 
〈/Channel〉 
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〈Channel name="PerCP-Cy5-5-A"> 
<ChannelValue name="FITC-A" value="-0.00000" /> 
<ChannelValue name='TerCP-Cy5-5-A" value=" 1.00000" /> 
</Channel> 
</CompensationMatrix> 
2.2.12.2. Compensation matrix for Annexin V-TMRM double-staining 
<CompensationMatrix name="20080209 AnnexinV 1 50 TMRM 0.5 uM 
(300 400) PE.mtx" prefix="Comp-" suffix="" version="Version 5.7.2”〉 
〈Channel name="FITC-A"> 
<ChannelValue name=”FITC-A" value=" 1.00000" /> 
<ChannelValue name=”PE-A” value="1.12435" /> 
〈/Channel〉 
〈Channel name="PE-A"> 
<ChannelValue name=”FITC-A" value="-0.00000" /> 
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2-2.12.3. Compensation matrix for CFSE-GPA double-staining 
<CompensationMatrix name="20080128 CFSE 5 uM GPA 1 1000 (550 350 
500) PE.mtx" prefix=”Comp-” suffix="" version="Version 5.7.2”〉 
〈Channel name="FITC-A"> 
<ChannelValue name="FITC-A" value=" 1.00000" /> 
〈ChannelValue name="PE-A" value="0.00141" /> 
〈/Channel〉 
〈Channel name:丨丨PE-A丨丨〉 
<ChannelValue name="FITC-A" value="0.65296" /> 
<ChannelValue name=”PE-A" value=" 1.00000" /> 
〈/Channel〉 
</CompensationMatrix> 
2.2.12.4. Compensation matrix for CFSE-TMRM double-staining 
<CompensationMatrix name="20080129 CFSE 5 uM TMRM 0.5 uM (550 
400 500) PE.mtx" prefix="Comp-" suffix="" version="Version 5.7.2”〉 
〈Channel name="FITC-A"> 
<ChannelValue name=”FITC-A" value=" 1.00000” /> 
<ChannelValue name=”PE-A” value=”0.03774” /> 
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〈/Channel〉 
〈Channel name="PE-A"> 
<ChannelValue name="FITC-A" value="0.07521" /> 
<ChannelValue name="PE-A" value=" 1.00000" /> 
〈/Channel〉 
</CompensationMatrix> 
2.2.12.5. Compensation matrix for CMH2DCFDA-GPA double-staining 
<CompensationMatrix name="20080209 CM-H2 10 uM GPA 1 1000 (280 
300) PE.mtx" prefix="Comp-" suffix="" version="Version 5.7.2”〉 
〈Channel name="FITC-A"> 
<ChannelValue name="FITC-A" value=" 1.00000" /> 
<ChannelValue name='TE-A" value="0.35321" /> 
〈/Channel〉 
〈Channel name="PE-A"> 
<ChannelValue name="FITC-A" value="-0.00000" /> 
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OR 
<CompensationMatrix name="20080209 CM-H2 10 uM GPA-2 1 500 (280 
350) PE.mtx" prefix="Comp-" suffix="" version="Version 5.7.2"> 
<Channel name="FITC-A"> 
<ChannelValue name=”FITC-A" value=" 1.00000" /> 
<ChannelValue name="PE-A" value=" 1.09872" /> 
〈/Channel〉 
〈Channel name="PE-A"> 
<ChannelValue name="FITC-A" value="-0.00000" /> 
<ChannelValue name=”PE-A” value=" 1.00000" /> 
〈/Channel〉 
</CompensationMatrix> 
2.2.12.6. Compensation matrix for GPA-TMRM double-staining 
<CompensationMatrix name="20080209 GPA 1 500 TMRM 0.5 uM (400 
400) PE.mtx" prefix="Comp-” suffix="” version^"Version 5.7.2”〉 
Channel name="FITC-A"> 
<ChannelValue name="FITC-A" value=" 1.00000" /> 
<ChannelValue name="PE-A" value="0.20775" /> 
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〈/Channel〉 
〈Channel name='TE-A"> 
<ChannelValue name="FITC-A" value="0.00755" /> 




Chapter 2 Materials and Methods 
2.3. Western blot 
Western blot was adopted to quantify target protein levels. Cells were lysed in SDS 
lysis buffer (1% w/v SDS, 1 mM NasVC^，10 mM Tris，pH 7.4) containing 1 mM 
PMSF and 1% v/v Protease Inhibitor Cocktail (Sigma P8340) for 1 h on ice. Samples 
were then boiled for 3 min and stored at -80 °C until use. Twenty-five \ig of protein 
extracts were separated by 12% SDS-PAGE and blotted to a PVDF membrane by 
wet transfer method. Iced-water was used to cool down the gel tank in both 
electrophoresis and blotting steps. After blotting, the membrane was first stained 
with IX Ponceau S solution for 5-10 min and washed in TEST until the red protein 
bands visualized. The membrane was then cut into pieces according to the target 
protein size and marker position. Subsequently, the membranes were blocked with 5% 
milk for 1 h and incubated with either anti-Glut 1 rabbit polyclonal antibody (1:1000) 
(Millipore AB1340/07-1401), anti-HIFla mouse monoclonal antibody (1:250) 
(Millipore MAB5382), anti-Fox03a rabbit polyclonal antibody (1:200) (Millipore 
07-702), anti-catalase rabbit polyclonal antibody (1:6000) (Calbiochem 219010), 
anti-MnSOD rabbit polyclonal antibody (1:4000) (Millipore 06-984), anti-
Cu/ZnSOD rabbit polyclonal antibody (1:4000) (Millipore 07-403)，anti-GPXl rabbit 
monoclonal antibody (1:250) (Cell Signaling #3286), anti-Trxl rabbit polyclonal 
antibody (1:250) (Cell Signaling #2285), anti-TrxRl rabbit polyclonal antibody 
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(1:250) (Millipore 07-613)，anti-Hsp-70 rabbit polyclonal antibody (1:5000) 
(Stressgen SPA-812C), or anti-p-actin mouse monoclonal antibody (1:1000) (Sigma 
A5316) in 5% milk for overnight at 4 °C. After washing, the membranes were 
incubated with horseradish peroxidase-conjugated anti-rabbit (Invitrogen 62-6120) or 
anti-mouse (81-6520) goat polyclonal antibody (1:10000) in 5% milk for 1 h at RT, 
washed, and developed with ECL detection reagent (GE Healthcare). 
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2.4. Statistical analysis 
Results were expressed as means 士 SD. The assumptions of the normality of data and 
the equivalency of variances were tested by Kolmogorov-Smimov Test and Levene 
Median Test, respectively. For two-group comparisons, Independent-samples T-Test 
was employed for parametric test and Mann-Whitney Rank Sum Test was employed 
for non-parametric test. Statistical significance was set at p<0.05 level. 
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3.1. The cells with high GPA staining were younger in cell lineage 
To investigate the proliferation states of cells underwent EPO-induced 
differentiation, the cells were stained with CFSE before differentiation, and then 
induced to differentiation by adding EPO to the culture medium. CFSE can stably 
label a population of cells such that their fluorescence is precisely halved at each 
successive cell generation (Oostendorp et al , 2000). Thus, i f the differentiating cells 
are younger cells, their CFSE fluorescence should be lower than the initial staining. 
In Figure 3.1 (Day 4)，we observed that most of the GPA+ cells were lower in CFSE 
fluorescence (upper left quadrant), indicating that these were younger cells. In 
contrast, the older cells with high CFSE fluorescence were GPA negative, i.e. 
undifferentiated cells. Thus, we can conclude that the differentiating TF-1 cells were 
younger in cell lineage. 
This finding is consistent with previous reports showing that erythroid 
proliferation is accompanied with differentiation (Goardon et al., 2006). In fact, 
CFU-Es, Pro EBs and Baso EBs are the most actively cycling cells in the bone 
marrow (40—50%) (Gregory and Eaves, 1978; Iscove, 1977) and these are exactly the 
three stages that TF-1 cells go through during EPO-induced erythropoiesis (Lui, 
2006). It is thus conceivable that the TF-1 cells actively proliferated during 
8b 
Chapter 3 Results and Discussion 
differentiation and that is why the younger cells expressed higher erythroid marker 
GPA. 
For the effect of vitamin E on cell proliferation (Figure 3.1), see section 3.4. 
3.2. ROS was produced during TF-1 erythropoiesis 
Whether ROS are produced during TF-1 erythropoiesis was tested by staining 
the cells with ROS sensitive fluorescent dye CM-H2DCFDA. In Figure 3.2, we 
observed a burst of ROS production (shadowed right rectangle) on Day 4 of EPO 
induction, indicating that ROS was produced during erythropoiesis. Double-staining 
the cells with ROS and GPA revealed that the majority of ROS+ cells were also 
GPA+ (upper right quadrant), indicating that ROS were mainly produced by 
differentiating cells (Figure 3.3). For example, on Day 4 of differentiation, the 
percentage of ROS+GPA+ population (upper right quadrant) was 30.23%, while that 
of the ROS+GPA— population (lower right quadrant) was only 9.02%. 
The percentage of ROS+ cells in Figure 3.3 was not identical with that in 
Figure 3.2，presumably because they were different batch of cells thus their response 
to EPO stimulation might be different. Nevertheless, the trend of ROS production 
was the same. 
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3.3. ROS production was not essential for TF-1 erythropoiesis 
Whether such ROS production is essential for erythropoiesis was tested by 
treating the cells with antioxidant vitamin E (Figure 3.3). Vitamin E significantly 
reduced the ROS production on any day of differentiation by keeping the ROS+ 
population (upper right + lower right quadrants) around 10% (Figures 3.3，3.4). 
However, the percentage of GPA+ cells (upper left + upper right quadrants) was not 
affected by vitamin E treatment (Figures 3.3, 3.5), indicating that ROS was not 
essential for erythropoiesis. 
In Figure 3.4 and 3.5，there was no statistically significant difference 
observed (p>0.05), mainly because of the small n number, i.e. the power of the 
performed tests was below the desired power. Therefore, more repeating experiments 
need to be conducted to increase the n number, i.e. the power of the tests. 
3.4. ROS production was not the cause of cell proliferation during TF-1 
erythropoiesis 
TF-1 cells actively proliferated during differentiation (Figure 3.1). ROS has 
been known to stimulate neonatal cardiac cell proliferation (Buggisch et al., 2007), 
however, it was not the stimulus for TF-1 cell proliferation. As shown in Figure 3.1 
(Day 4)，vitamin E treatment had no effect on the percentage of CFSE-low 
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population (upper left + lower left quadrants), showing that ROS neutralization did 
not affect cell proliferation during erythropoiesis. 
3.5. ROS production was not the cause of sub-lethal mitochondrial 
depolarization in TF-1 erythropoiesis 
Our lab has previously found that mitochondrial depolarization is a non-
apoptotic requirement during TF-1 erythropoiesis (Lui and Kong, 2007). Other 
apoptotic mechanisms, such as the release of cytochrome c and AIF from 
mitochondria, and the activation of caspase-3 were also non-apoptotic requirements 
of erythropoiesis (Carlile et al., 2004; Kolbus et al., 2002; Lui and Kong, 2006, 2007; 
Testa, 2004; Zermati et al., 2001). However, the cause of mitochondrial 
depolarization remains unknown. 
Increased mitochondrial ROS can lead to mitochondrial DNA damage, 
mitochondrial malfunction, cytochrome c release, and cell death (Fariss et al, 2005; 
Madesh and Hajnoczky, 2001; Melov et al , 1999; Orrenius et al., 2007). It was thus 
possible that ROS production caused mitochondrial depolarization in TF-1 cells 
during erythropoiesis. 
We tested this hypothesis by staining the cells with a A^m sensitive dye 
TMRM. On Day 2 of EPO treatment, 34.19% of the cells were low in A^m (lower 
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left quadrant), compared to the 7.46% on Day 0. This low A平m population 
decreased to 22.69% on Day 4 and then to 〜I30/0 on Day 6 and 8 (Figure 3.6)， 
indicating that the cells had their mitochondria repolarized (recovered) after 
depolarization. The peak day of mitochondrial depolarization (Day 2) seemed to be 
two days earlier than the peak of ROS production at Day 4 (Figure 3.4). In addition, 
antioxidant vitamin E treatment did not rescue the loss of A ^ m (lower left quadrant) 
at any time during differentiation (Figure 3.6). These observations confirmed that 
ROS was not the cause of mitochondrial depolarization. 
In fact, more A平m depolarizing cells were found in vitamin E treated group 
on all days of treatment (Figures 3.6，3.7, 3.8). Why vitamin E caused more 
mitochondrial depolarization is still unknown. Possible explanations may involve the 
localization of the lipophilic vitamin E to the mitochondrial membrane (Smith et al., 
1999) and its interference with the repolarization of the mitochondria in TF-1 cells. 
The specific binding of Annexin V to phosphatidyl-serine (PS) allows the 
detection of cells with externalized PS, i.e. dying cells. In Figure 3.6，we found that a 
large portion of the low A平m cell population was annexin V negative (lower left 
quadrant), indicating that they were actually viable. Thus, the mitochondrial 
depolarization in TF-1 erythropoiesis was sub-lethal. Similarly, apoptotic-like 
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depolarization of the mitochondria, release of cytochrome c and AIF are not lethal 
during keratinocyte differentiation (Tamiji et al., 2005). 
Since erythroids lose their mitochondria during maturation, the loss of 
mitochondria mass may interfere with the detection of A平m. Thus, a control 
experiment was carried out by staining the cells with fluorescent dye NAO. NAO 
binds to cardiolipin on the inner mitochondrial membrane and is mitochondrion-
specific. Such binding is not affected by A平m (Metivier et al., 1998). NAO can thus 
be used to quantify mitochondrial mass. In Figure 3.9, we found that there was no 
much change in mitochondrial mass during the assay period (shadowed left 
rectangle). Therefore, the change of A中m in this study was not due to the change of 
mitochondrial mass. 
3.6. The cells showing mitochondrial depolarization were mother cells that gave 
rise to differentiating cells 
To reveal the differentiation status of the cells with mitochondrial 
depolarization, the cells were double-stained with GPA and TMRM (Figure 3.7). It 
was observed that on any days of differentiation, the majority of GPA+ cells were 
high in TMRM staining (upper right quadrant). In contrast, the majority of TMRM 
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low cells were low in GPA staining (lower left quadrant), indicating that the cells 
with mitochondrial depolarization were undifferentiated cells. 
We designed another experiment to verify this finding. The cells were stained 
with CFSE before differentiation, and then induced to differentiation by adding EPO 
to the culture medium. On alternative days of differentiation, the cells were stained 
with TMRM to reveal the cell lineage that had their mitochondria depolarized 
(Figure 3.8). There was a trend that the cells with mitochondrial depolarization 
(TMRM low) were higher in CFSE fluorescence, indicating that many of these cells 
were older cells. In contrast, most of the younger cells (CFSE lower) were high in 
TMRM staining. 
These results, together with our lab's previous finding that mitochondrial 
depolarization is a non-apoptotic requirement during TF-1 erythropoiesis (Lui and 
Kong, 2007)，infer that the older, undifferentiated mother cells had their 
mitochondrial depolarized to give rise to younger, differentiating cells. 
3.7. ROS production was not the cause of cell death in TF-1 erythropoiesis 
As aforementioned, excessive ROS (i.e. oxidative stress) can induce 
apoptosis (Fruehauf and Meyskens, 2007). In Figure 3.6，we observed that around 10% 
of the cells were positive in annexin V staining during TF-1 erythropoiesis (right 
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rectangle). Those were the cells with PS extemalization, a hallmark of dying cells. 
Antioxidant vitamin E treatment did not rescue the percentage of dying cells (right 
rectangle), indicating that ROS production did not induce cell death. 
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3.8. ROS production confers oxidative defense during TF-1 erythropoiesis 
3.8.1. Glutl inhibition partially blocked TF-1 erythropoiesis without affecting 
cell viability 
Given the importance of Glutl and glucose in human erythrocytes, the 
inhibition of Glutl expression and function may affect erythropoiesis and/or cell 
viability. Knocking-down the Glutl gene by using Glutl-specific siRNA was 
considered, however, the TF-1 cells were relatively weak under transfection stress as 
opposite to some easy-to-transfect cancer cell lines such as HepG2. Thus, we turned 
to seek for chemicals that can inhibit Glutl gene function. The pan-Glut inhibitor 
cytochalasin B was not used in our experiments because of its cytotoxicity and lack 
of specificity. Instead, we employed a widely used antibiotic levofloxacin, a third 
generation fluoroquinolone. Levofloxacin is one of the most prescribed antibiotic 
clinically (Under et al., 2005). However, dysglycemia (hypoglycemia or 
hyperglycemia) are known adverse effects of levofloxacin (Coblio et al., 2004; 
Mehlhom and Brown, 2007; Park-Wyllie et al., 2006). Previously, we have shown 
that levofloxacin and other two fluoroquinolones reduce Glutl mRNA expression, 
cell surface Glutl protein expression and glucose transport in vitro, which may help 
explain the fluoroquinolone-induced dysglycemia (Ge et al., 2009; Ge et al., 2007). 
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Thus，the inhibitory effect of levofloxacin on Glutl gene expression and function has 
been validated. 
Levofloxacin treatment during TF-1 erythropoiesis partially inhibited the 
percentage of cells with high GPA staining (upper left + upper right quadrants) 
(Figures 3.10，3.11). Such an inhibition was not the result of cell death, since 
levofloxacin did not affect the percentage of dying cells on any day of differentiation 
(right rectangle) (Figure 3.12). Thus, it is possible that levofloxacin partially blocked 
erythropoiesis because of its inhibitory effect on Glutl expression and function (Ge 
et al., 2009). These results showed that Glutl and glucose uptake may be important 
for TF-1 erythropoiesis. 
3.8.2. Antioxidant defense systems were established during TF-1 erythropoiesis 
As aforementioned, mature red cells are deprived of all capacity of protein 
synthesis. Thus, they have to rely on antioxidant defense systems established earlier 
in erythropoiesis to protect themselves from ROS damage. In fact, Foxo3-null 
erythropoiesis exhibited decreased expression of ROS scavenging enzymes such as 
catalase, MnSOD and GPxl, and the mature red cells had ROS-mediated shortened 
lifespan and evidence of oxidative damage (Marinkovic et al., 2007). 
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Whether antioxidant enzymes were upregulated during TF-1 erythropoiesis 
was tested by Western blot. Catalase, Cu/ZnSOD, MnSOD, GPx，Trx and TrxR were 
probed (Figure 3.13). It was found that while some of them were partially 
upregulated on later days of differentiation, the upregulation of GPxl and Trxl were 
earlier and especially significant. GPx and Trx are key enzymes of the GPx and Prx 
peroxide scavenging systems, respectively. In concert with our findings, it has been 
reported that the Prx2 protein is induced and accumulated at early stages of erythroid 
differentiation (Rabilloud et al., 1995). 
Given the importance of NADPH in peroxide scavenging systems and the 
importance of glucose in regenerating NADPH, we were next curious to know the 
expression of Glutl , the sole glucose transporter in erythrocytes, during TF-1 
erythropoiesis. Western blot showed that the expression level of glycosylated cell 
surface Glutl (upper band as indicated by the black arrow) were significantly 
upregulated from Day 4 of EPO treatment (Figure 3.14). Keeping in mind that there 
were both GPA+ (differentiating) and GPA- (undifferentiated) cell populations in our 
TF-1 system, we separated the GPA+ cells from the GPA- population by FACS cell 
sorting (shadowed right rectangle) (Figure 3.15A), and probed Glutl expression 
respectively (Figure 3.15B). The cell surface Glutl upregulation was only found in 
GPA+ cells, but not GPA- cells, indicating that the cells with Glutl upregulated were 
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differentiating cells. This finding was consistent with the work of Montel-Hagen et al. 
on the induced erythropoiesis of human CD34+ cells isolated from umbilical cord 
blood (Montel-Hagen et a l , 2008). The increased Glutl expression on cell surface 
may enhance glucose and vitamin C uptake, thus provides the cells with more 
reducing equivalents against oxidative stress (Klepper et al., 1998; Montel-Hagen et 
a l , 2008). 
To test whether the upregulation of antioxidant enzymes and Glutl provided 
the cells with more resistance to oxidative damage, we challenged the EPO-treated 
TF-1 cells with exogenous H2O2 during the course of differentiation (Figure 3.16). 
The percentage of Annexin V+ cells (upper right + lower right quadrants) were: 
44.18% on Day 0, 51.24% on Day 2，40.84% on Day 4，37.25% on Day 6 and 29.92% 
on Day 8. It was obvious that on later days of differentiation, the cells became more 
resistant to H2O2 challenge as the percentage of Annexin V+ cells became less. This 
finding correlated well with the observed upregulation of various antioxidant 
enzymes and Glutl (Figures 3.13，3.14). It seems clear that antioxidant defense 
systems are established during erythropoiesis. 
However, the mechanisms involved in this process are largely unknown. In 
this study, we proposed that ROS production during erythropoiesis triggers the 
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upregulation of antioxidant defense systems, which may be one of the mechanisms 
for erythroids to prepare themselves against future oxidative challenge. 
3.8.3. Antioxidant treatments blocked the establishment of antioxidant defense 
systems during TF-1 erythropoiesis 
Excessive ROS can exert detrimental effects to cellular organelles and 
molecules. To avoid this, when a amount of ROS was produced in a cell, the cell 
would respond by promoting the transcription of various antioxidant enzymes and 
related proteins by ROS-regulated transcription factors such as p53, Nrf2, NF-KB 
and AP-1 (Brigelius-Flohe, 2006; Ding et al., 2008; Hughes et al., 2005; Sablina et 
al , 2005; Sun and Oberley, 1996). Furthermore, ROS has been known to activate 
Glutl and increase glucose uptake (Na et al., 2007; Prata et al., 2008). This scenario 
may be true for the TF-1 system, since we already observed ROS production (Figure 
3.4) and the upregulation of antioxidant enzymes (Figure 3.13) and Glutl (Figure 
3.14). Thus, our next step was to test the hypothesis that ROS production triggers the 
establishment of antioxidant defense systems during TF-1 erythropoiesis. 
Firstly, the cells were treated with antioxidant EUK-134 during EPO-induced 
erythropoiesis. EUK-134 is a synthetic SOD and catalase mimic possessing both 02._ 
and H2O2 dismutation activities (Rong et al, 1999). It belongs to the salen class of 
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catalytic antioxidants, which are not very selective and can react with other peroxides 
(Day，2009). EUK-134 treatment partially inhibited the expression levels of Glutl, 
catalase and Cu/ZnSOD, but had no effect on the expression level of MnSOD 
(Figure 3.17). 
Secondly, the cells were treated with vitamin E during the course of 
differentiation. Vitamin E is a lipophilic non-enzymatic antioxidant. It is the most 
effective antioxidant for terminating the chain reactions of lipid peroxidation in cell 
membranes (Cimen, 2008). Limited evidence showed that vitamin E treatment might 
partially inhibit the upregulation of glycosylated cell surface Glutl (upper band as 
indicated by the black arrow) in GPA+ populations (Figure 3.18，lower panel), but 
had no effect on the expression level of catalase, Cu/ZnSOD or MnSOD (Figure 3.18, 
upper panel). To test whether vitamin E treatment blocked the establishment of 
antioxidant defense systems, we challenged the cells with exogenous H2O2 during 
the course of differentiation (Figure 3.19). The percentage of Annexin V+ cells 
(upper right + lower right quadrants) were: 37.79% on Day 2，28.08% on Day 4， 
28.56% on Day 6 and 18.71% on Day 8. When comparing to the control group 
(Figure 3.16), it was found that vitamin E provided the cells with even more 
resistance to H2O2 challenge. This finding was reasonable because 1) vitamin E did 
not affect the expression level of antioxidant enzymes that we assayed, and 2) some 
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studies showed that vitamin E can be incorporated into the cell membranes and thus 
the intracellular half-life of vitamin E can be as long as 14-20 h (Sakagami et al., 
1997). Therefore, it is possible that during the 9 h of H2O2 challenging in our 
experimental setup, intracellularly accumulated vitamin E per se continued to protect 
the cells from oxidative stress. This additional layer of defense was a bonus to the 
cell's native defense system and was a defect in our experimental design. 
Thirdly, the cells were treated with vitamin C during erythropoiesis. Vitamin 
C is a water soluble non-enzymatic antioxidant. It can donate a hydrogen atom to a 
free radical molecule thereby neutralizing it (Cimen, 2008). Limited evidence 
showed that vitamin C treatment might partially inhibit the upregulation of 
Cu/ZnSOD, while had no effect on the expression level of catalase and MnSOD 
(Figure 3.20). To test whether vitamin C treatment blocked the establishment of 
antioxidant defense systems, we challenged the cells with exogenous H2O2 during 
the course of differentiation (Figure 3.21). The percentage of Aimexin V+ cells 
(upper right + lower right quadrants) were: 55.56% on Day 2, 48.81% on Day 4, 
49.65% on Day 6 and 60.14% on Day 8. Instead of becoming more resistant to H2O2 
challenging as seen in the control group (Figure 3.16)，the cells treated with vitamin 
C during differentiation did not develop such resistance. This finding correlates well 
with the inhibited expression of Cu/ZnSOD by vitamin C treatment. It is noteworthy 
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that the half-life of intracellular vitamin C is only 1 h (Waring and Schorah, 1998). 
Therefore, the protective role of intracellular vitamin C per se in the H2O2 challenge 
experiments should be rather limited. 
Lastly, the cells were treated with another antioxidant NAC during 
differentiation. NAC is a GSH precursor which acts in the GPx system to diminish 
peroxides. Under H2O2 challenging, the percentage of Annexin V+ cells (upper right 
+ lower right quadrants) were: 50.57% on Day 2, 41.25% on Day 4，41.58% on Day 
6 and 40.03% on Day 8 (Figure 3.22). Similar to vitamin C, the cells treated with 
NAC during erythropoiesis did not develop enough resistance as compared to control 
(Figure 3.16). GSH is rapidly consumed under H2O2 challenging, thus, similar to 
vitamin C, the protective role of NAC per se in the challenging experiments should 
be limited. 
A summary of the H2O2 challenging experiments on cell death can be found 
in Figure 3.23. The effects of EUK-134, vitamin E, vitamin C and NAC on TF-1 
cells showed that when ROS production during erythropoiesis was blocked, the 
upregulation of some antioxidant enzymes/related proteins and the acquisition of 
antioxidant defense systems might also be blocked. Thus, during erythropoiesis, ROS 
may be the signal that induce the cell's antioxidant defense. Such defense including 
enzymatic and non-enzymatic antioxidants can be stored in the mature RBCs to cope 
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with one of the highest level of oxidative stress conditions in the human body when 
they transport oxygen. 
Given the difference in their chemical properties, cellular localization, mode 
of ROS neutralization and the type of ROS species neutralized, it is reasonable that 
the effects of various antioxidants were not the exactly the same. In erythroids, the 
endogenous source of ROS can be the heme synthesis pathway (Ryter and Tyrrell, 
2000)，NADPH oxidase (Xiao et al., 2009), mitochondrial respiratory chain (Gil et 
al., 2003), or many others (Sauer et al., 2001). ROS are rapidly generated, highly 
diffusible and easily degraded. Therefore, the detection of ROS production or 
neutralization has been very difficult. To explore the ROS neutralization mechanisms 
underlying each antioxidant is thus beyond the scope of this study. 
3.9. Conclusion 
In this study, the production and possible roles of ROS in TF-1 erythropoiesis 
were examined. Two conclusions can be drawn from the results: 
1. ROS were produced in differentiating cells during EPO-induced 
erythropoiesis in TF-1 cells. 
2. ROS production was not essential for erythropoiesis in TF-1 cells. It was not 
the cause of cell proliferation, sub-lethal mitochondrial depolarization, or cell 
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death during erythropoiesis. Instead, ROS production confers oxidative 
defense to protect the erythroids from oxidative stress. 
These findings may contribute to our understanding of the difference between 
normal erythropoiesis and that in blood diseases such as G6PD deficiency, anemia or 
leukemia. Better treatments may be developed in the future for the cure of these 
diseases. 
3.10. Future work 
Our study showed that two antioxidant enzymes (GPxl and Trxl) were 
significantly upregulated during erythropoiesis (Figure 3.13). Thus, these two 
enzymes may be the most important factor determining the antioxidant defense 
strength of the erythroids. Whether antioxidant treatments such as NAC affect the 
upregulation of these two enzymes and other enzymes of the GPx and Prx systems 
should be investigated. 
Although one contribution of ROS production to erythropoiesis has been 
found, the source of ROS production is still unknown and worth investigating. As 
mentioned before, the endogenous source of ROS can be the heme synthesis pathway 
(Ryter and Tyrrell, 2000), NADPH oxidase (Xiao et al., 2009)，mitochondrial 
respiratory chain (Gil et al , 2003), peroxisomes, cytochrome P450, xanthine oxidase, 
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cyclooxygenase, among others (Sauer et al., 2001). We propose that ROS production 
in TF-1 erythropoiesis may be a byproduct of the heme synthesis pathway, since the 
peak day of ROS production (Day 4) is the day on which we began to observe 
significant change of the color of cell pellet from white to red, indicating dramatic 
hemoglobin synthesis. This hypothesis may be substantiated by inhibiting the heme 
synthesis pathway using succinylacetone or isonicotinic acid hydrazide (Muta and 
Krantz, 1995)，and monitor the ROS production during erythropoiesis. 
The pathways by which ROS activate the expression of antioxidants enzymes 
and Glutl are also interesting to study, which may involve redox-regulated 
transcription factors such as Nr£2 and HIFla. As an example, HIF la is a known 
transcription factor of the Glutl gene (Chen et al., 2001), and ROS has been known 
to regulate the activity of HIF la and therefore regulate the HIF-mediated gene 
expression (Gorlach and Kietzmann, 2007; Kietzmann and Gorlach, 2005; Martinez-
Sanchez and Giuliani, 2007). The possible regulation of ROS on Glutl through 
HIF la may be proved by probing the expression level of HIF la during normal 
erythropoiesis and erythropoiesis with ROS depleted. 
The role of ROS production in G6PD-deficient erythropoiesis is an important 
question to ask. Presumably, due to the decreased amount of NADPH in those cells, 
ROS production could be elevated, which may exceed the cell's defense limit and 
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pose oxidative stress on the differentiating cells. Decreased efficacy in producing 
mature RBC may be a consequence. Our lab is currently working on the knockdown 
of the G6PD gene in TF-1 cells using BLOCK-iT™ Pol I I miR RNAi Expression 
Vector with EmGFP and G6PD BLOCK-ITTM miR RNAi Select (Invitrogen). The 
stable transfection of the RNAi expression vector into the cells can ensure long-term 
knockdown of the G6PD gene, and the co-expression of EmGFP provides a direct 
internal marker to screen out the cells with successful RNAi expression in flow 
cytometry or confocal microscopy experiments. When the G6PD-knockdown TF-1 
cell line is generated, erythropoiesis can be induced. Differentiation and ROS 
production can be assayed by flow cytometry. Antioxidant enzymes involved in the 
GPx pathway can be probed, and the differentiating cells with G6PD-knockdown can 
be challenged by oxidative stress. 
Apart from these in vitro experiments, animal study using G6PD-null mouse 
can be further adopted to answer this question. Erythroid progenitor cells may be 
isolated from the bone marrow of the mouse, and ex vivo erythropoiesis can be 
induced. Furthermore, the efficacy of mature RBC production in G6PD-null mouse is 
worth investigating. 
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Figure 3.1. Cell lineage versus erythroid marker during erythropoiesis under 
vitamin E treatment. The cells were stained by CFSE before induced to 
differentiation. During erythropoiesis, erythroid marker GPA was stained by anti-
GPA antibody, and analyzed by flow cytometry as described. Cells treated with 100 
|J,M of vitamin E (VE) during differentiation were compared with control cells. 
Renewal of EPO (10 ng/ml) and VE were done every two days together with the 
renewal of medium. Cell density was kept at 4x10^ cells/ml. Days and methods of 
treatment were indicated in the Sample Name above each figure. X-axis, cell lineage; 
Y-axis, erythroid marker. Numbers at the comers of each figure represents the 
percentage of cells in the corresponding quadrants. 
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Figure 3.2. ROS production during erythropoiesis. For the induction of 
erythropoiesis, TF-1 cells at a density of 4x1 O^  cells/ml were treated with M2 
medium containing EPO at 37 °C, 5% CO2. Renewal of EPO (10 ng/ml) were done 
every two days together with the renewal of medium. Cell density was kept at 4x10^ 
cells/ml. During erythropoiesis, ROS production was assayed by CM-H2DCFDA 
staining, and analyzed by flow cytometry as described. Days of treatment were 
indicated in the Sample Name above each figure. X-axis, ROS level; Y-axis, cell 
number. Number at the upper-right comer of each figure represents the percentage of 
cells in the shadowed area. 
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Figure 3.3. ROS production versus erythroid marker during erythropoiesis 
under vitamin E treatment. During erythropoiesis, ROS production and erythroid 
marker GPA were double-stained by CM-H2DCFDA and anti-GPA antibody, and 
analyzed by flow cytometry as described. Cells treated with 100 |iM of vitamin E 
(VE) during differentiation were compared with control cells. Renewal of EPO (10 
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ng/ml) and VE were done every two days together with the renewal of medium. Cell 
density was kept at 4x10^ cells/ml. Days and methods of treatment were indicated in 
the Sample Name above each figure. X-axis, ROS level; Y-axis, erythroid marker. 
Numbers at the comers of each figure represents the percentage of cells in the 
corresponding quadrants. 
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Figure 3.4. Percentage of ROS+ cells in vitamin E-treated TF-1 erythropoiesis as 
compared to control. Derived from flow cytometry data by summing up the 
percentage of cells in the red rectangular region (shown at top). Data from two 
independent experiments (n=2). Results were expressed as means 士 SD. Mann-
Whitney Rank Sum Test was adopted for the comparison between EPO treated days 
and Day 0, or between control and VE groups on one specific day of treatment. 
p=0.333 for all comparisons, thus there is not a statistically significant difference. X-
axis, days of treatment; Y-axis, percentage of ROS+ cells. 
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Whitney Rank Sum Test was adopted for the comparison between EPO treated days 
and Day 0, or between control and VE groups on one specific day of treatment. 
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PS Externalization (Annexin V-GFP) 
Figure 3.6. Cell death versus mitochondrial transmembrane potential (A^m) 
during erythropoiesis under vitamin E treatment. During EPO-induced TF-1 
erythropoiesis, cell death (indicated by PS externalization) and were double-
stained by annexin V-GFP and TMRM, and analyzed by flow cytometry as described. 
Cells treated with 100 \xM of vitamin E (VE) during differentiation were compared 
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with control cells. Renewal of EPO (10 ng/ml) and VE were done every two days 
together with the renewal of medium. Cell density was kept at 4x1 O^  cells/ml. Days 
and methods of treatment were indicated in the Sample Name above each figure. X-
axis, PS extemalization; Y-axis, A中m. Numbers at the comers of each figure 
represents the percentage of cells in the corresponding quadrants. 
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Erythroid Marker (Anti-GPA Antibody) 
Figure 3.7. Erythroid marker versus mitochondrial transmembrane potential 
(A^m) during erythropoiesis under vitamin E treatment. During EPO-induced 
TF-1 erythropoiesis, erythroid marker GPA and A平m were double-stained by anti-
GPA antibody and TMRM, and analyzed by flow cytometry as described. Cells 
treated with 100 of vitamin E (VE) during differentiation were compared with 
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control cells. Renewal of EPO (10 ng/ml) and VE were done every two days together 
with the renewal of medium. Cell density was kept at 4x10^ cells/ml. Days and 
methods of treatment were indicated in the Sample Name above each figure. X-axis, 
erythroid marker; Y-axis, A平m. Numbers at the comers of each figure represents the 
percentage of cells in the corresponding quadrants. 
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(To be continued) 
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Figure 3.8. Cell lineage versus mitochondrial transmembrane potential (A^m) 
during erythropoiesis under vitamin E treatment. The cells were stained by CFSE 
before differentiation induction. During erythropoiesis, A¥m was stained by TMRM, 
and analyzed by flow cytometry as described. Cells treated with 100 |iM of vitamin 
E (VE) during differentiation were compared with control cells. Renewal of EPO (10 
ng/ml) and VE were done every two days together with the renewal of medium. Cell 
density was kept at 4x 1ce l ls /ml . Days and methods of treatment were indicated in 
the Sample Name above each figure. The last two figures were Day 8 cells treated 
with 50 nM potassium ionophore valinomycin to depolarize the zVFm intentionally 
(positive controls). X-axis, cell lineage; Y-axis, A中m. Numbers at the comers of 
each gate represents the percentage of cells in the corresponding gate. 
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Figure 3.9. Change of mitochondrial mass during erythropoiesis. During 
erythropoiesis, mitochondrial mass was probed by NAO staining, and analyzed by 
flow cytometry as described. Days of treatment were indicated in the Sample Name 
above each figure. X-axis, mitochondrial mass; Y-axis, cell number. Number at the 
upper-left comer of each figure represents the percentage of cells in the shadowed 
area. 
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ROS (CM-H2DCFDA) 
Figure 3.10. ROS production versus erythroid marker during erythropoiesis 
under levofloxacin treatment. During erythropoiesis, ROS production and 
erythroid marker GPA were double-stained by CM-H2DCFDA and anti-GPA 
antibody, and analyzed by flow cytometry as described. Cells treated with 7.06 |aM 
of levofloxacin (LevolX) during differentiation were compared with control cells. 
Renewal of EPO (10 ng/ml) and levofloxacin were done every two days together 
with the renewal of medium. Cell density was kept at 4x10^ cells/ml. Days and 
methods of treatment were indicated in the Sample Name above each figure. X-axis, 
ROS level; Y-axis, erythroid marker. Numbers at the comers of each figure 
represents the percentage of cells in the corresponding quadrants. 
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Figure 3.11. Percentage of GPA+ cells in levofloxacin-treated TF-1 
erythropoiesis as compared to control. Derived from Figure 3.10 by summing 
up the percentage of cells in the red rectangular of flow cytometry data (shown 
at top). X-axis, days of treatment; Y-axis, percentage of GPA+ cells. n=l. 
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PS Externalization (Annexin V-GFP) 
Figure 3.12. Cell death versus mitochondrial transmembrane potential (A^m) 
during erythropoiesis under levofloxacin treatment. During EPO-induced TF-1 
erythropoiesis, cell death (indicated by PS externalization) and A ^ m were double-
stained by annexin V-GFP and TMRM, and analyzed by flow cytometry as described. 
Cells treated with 7.06 [ iM of levofloxacin (LevolX) during differentiation were 
compared with control cells. Renewal of EPO (10 ng/ml) and levofloxacin were done 
every two days together with the renewal of medium. Cell density was kept at 4x10^ 
cells/ml. Days and methods of treatment were indicated in the Sample Name above 
each figure. X-axis, PS externalization; Y-axis, A中m. Numbers at the comers of 
each figure represents the percentage of cells in the corresponding quadrants. 
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Figure 3.13. Expression level of antioxidant enzymes during erythropoiesis. 
During EPO-induced TF-1 erythropoiesis, proteins were extracted from whole cell 
lysate on alternative days. Western blot was carried out as described. Beta-actin 
served as an internal control. Days of treatment were indicated below each figure. 
n=l-3. 
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Figure 3.14. Expression level of Glutl during erythropoiesis. During EPO-
induced TF-1 erythropoiesis, proteins were extracted from whole cell lysate on 
alternative days. Western blot was carried out as described. Beta-actin served as an 
internal control. Days of treatment were indicated below each figure. The black 
arrow indicates the glycosylated cell surface Glutl with larger molecular weight. n=l. 
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Figure 3.15. Expression level of Glutl in GPA positive and GPA negative 
populations. (A) On Day 8 of differentiation, the TF-1 cells were labeled with anti-
GPA antibody, and then sorted by FACS based on GPA labeling as described. The 
left figure shows the population considered as GPA positive, while the right figure 
shows the population considered as GPA negative. X-axis, erythroid marker; Y-axis, 
cell number. (B) On Day 4 and 8 of EPO treatment, GPA+ and GPA- cell 
populations were separated by GPA labeling and FACS cell sorting as described in 
(A). The two populations were lysed separately and subjected to Western blot. 
Subsequently, Glutl expression was probed as described. n=l. 
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Figure 3.16. Cell death under oxidative stress challenging during erythropoiesis. 
During EPO-induced TF-1 erythropoiesis, cells were challenged with 2 mM H2O2 for 
9 h before the cell death determination assay, then double-stained by annexin V-GFP 
and PI, and analyzed by flow cytometry as described. Days of treatment were 
indicated in the Sample Name above each figure. X-axis, PS externalization; Y-axis, 
membrane integrity. Numbers at the comers of each figure represents the percentage 
of cells in the corresponding quadrants. 
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Figure 3.17. Expression level of antioxidant enzymes and Glutl during 
erythropoiesis under EUK-134 treatment. During EPO-induced TF-1 
erythropoiesis, proteins were extracted from whole cell lysate on alternative days. 
Cells treated with 50 |LIM of EUK-134 during differentiation were compared with 
control cells. Renewal of EPO (10 ng/ml) and EUK-134 were done every two days 
together with the renewal of medium. Cell density was kept at 4x10^ cells/ml. 
Western blot was carried out as described. Beta-actin served as an internal control. 
Days and methods of treatment were indicated below each figure. M, marker. n=l. 
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Figure 3.18. Expression level of antioxidant enzymes and Glutl during 
erythropoiesis under vitamin E treatment. During EPO-induced TF-1 
erythropoiesis, proteins were extracted from whole cell lysate on alternative days. 
Cells treated with 100 | iM of vitamin E (VE) during differentiation were compared 
with control cells. Renewal of EPO (10 ng/ml) and VE were done every two days 
together with the renewal of medium. Cell density was kept at 4x10^ cells/ml. 
Western blot was carried out as described. Beta-actin served as an internal control. 
Days and methods of treatment were indicated below each figure. M，marker. On 
Day 8 of EPO (with or without VE) treatments, GPA+ and GPA- cell populations 
within each sample were separated by GPA labeling and FACS cell sorting. The two 
populations were lysed separately and subjected to Western blot. Subsequently, 
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Glutl expression was probed as described. The black arrow indicates the 
glycosylated cell surface Glutl with larger molecular weight. n=l-2. 
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Figure 3.19. Cell death under oxidative stress challenging during erythropoiesis 
under vitamin E treatment. During EPO-induced TF-1 erythropoiesis, cells were 
treated with 100 \xM of vitamin E (VE) during differentiation. Renewal of EPO (10 
ng/ml) and VE were done every two days together with the renewal of medium. Cell 
density was kept at 4x10^ cells/ml. On alternative days, the cells were challenged 
with 2 mM H2O2 for 9 h before the cell death determination assay, then double-
stained by annexin V-GFP and PI, and analyzed by flow cytometry as described. 
Days and method of treatment were indicated in the Sample Name above each figure. 
X-axis, PS externalization; Y-axis, membrane integrity. Numbers at the comers of 
each figure represents the percentage of cells in the corresponding quadrants. 
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Figure 3.20. Expression level of antioxidant enzymes during erythropoiesis 
under vitamin C treatment. During EPO-induced TF-1 erythropoiesis, proteins 
were extracted from whole cell lysate every four days. Cells treated with 100 [iM of 
vitamin C (VC) during differentiation were compared with control cells. Renewal of 
EPO (10 ng/ml) and VC were done every two days together with the renewal of 
medium. Cell density was kept at 4x1 O^  cells/ml. Western blot was carried out as 
described. Beta-actin served as an internal control. Days and methods of treatment 
were indicated below each figure. n=l. 
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Figure 3.21. Cell death under oxidative stress challenging during erythropoiesis 
under vitamin C treatment. During EPO-induced TF-1 erythropoiesis, cells were 
treated with 100 \xM of vitamin C (VC) during differentiation. Renewal of EPO (10 
ng/ml) and VC were done every two days together with the renewal of medium. Cell 
density was kept at 4x10^ cells/ml. On alternative days, the cells were challenged 
with 2 mM H2O2 for 9 h before the cell death determination assay, then double-
stained by annexin V-GFP and PI, and analyzed by flow cytometry as described. 
Days and method of treatment were indicated in the Sample Name above each figure. 
X-axis, PS externalization; Y-axis, membrane integrity. Numbers at the comers of 
each figure represents the percentage of cells in the corresponding quadrants. 
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Figure 3.22. Cell death under oxidative stress challenging during erythropoiesis 
under NAC treatment. During EPO-induced TF-1 erythropoiesis, cells were treated 
with 5 mM of NAC during differentiation. Renewal of EPO (10 ng/ml) and NAC 
were done every two days together with the renewal of medium. Cell density was 
kept at 4x10^ cells/ml. On alternative days, the cells were challenged with 2 mM 
H2O2 for 9 h before the cell death determination assay, then double-stained by 
annexin V-GFP and PI, and analyzed by flow cytometry as described. Days and 
method of treatment were indicated in the Sample Name above each figure. X-axis, 
PS extemalization; Y-axis, membrane integrity. Numbers at the comers of each 
figure represents the percentage of cells in the corresponding quadrants. 
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Figure 3.23. Summary of oxidative stress challenging during erythropoiesis. 
Derived from Figures 3.16, 3.19, 3.21, 3.22 by summing up the percentage of 
cells in the red rectangular of flow cytometry data (shown at top). X-axis, days 
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